Find winning stocks in any market cycle. Join 7 million investors using Simply Wall St’s investing ideas for FREE.

Bio-Techne (TECH) has drawn fresh investor interest after teaming up with Refeyn on a four hour integrated workflow that links charge heterogeneity, molecular weight, and aggregation in bispecific antibodies and biosimilars at single molecule resolution.

See our latest analysis for Bio-Techne.

That Refeyn collaboration has landed at a time when momentum in Bio-Techne’s share price has picked up, with a 1 month share price return of 29.7% and a 90 day gain of 10%, even though the year to date share price return is still down 5.8% and the 3 year total shareholder return is down 27.3%.

If you like the R&D angle…